Non-pegylated Liposomal Doxorubicin (Myocet ®) Plus Docetaxel (Taxotere ®) (MYTAX), as First-line Chemotherapy (CHT), in Metastatic Breast Cancer (MBC): Results of a Phase II Study

被引：0
|
作者：
Imperatori, L. [1 ]
Lippe, P. [1 ]
Trapuzzano, C. [1 ]
Laici, G. [1 ]
Cappelletti, C. [1 ]
Tamburrano, T. [1 ]
Mattioli, R. [1 ]
机构：
[1] Osped Santa Croce, Fano, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71517-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [1] A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCET®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer
    Vanturini, M.
    Bighin, C.
    Puglisi, F.
    Contu, A.
    Aitini, E.
    Colucci, G.
    Merlano, M. C.
    Paccagnella, A.
    Marini, G.
    Crino, L.
    Djazouli, K.
    Barbato, A.
    CANCER RESEARCH, 2009, 69 (02) : 249S - 249S
  • [2] Phase II trial of non-pegylated liposomal doxorubicin (Myocet®) associated with weekly docetaxel in metastatic breast cancer
    Safina, V.
    Giuntini, N.
    Coltelli, L.
    Martella, F.
    Di Marsico, R.
    Bejtja, E.
    Giannessi, P. G.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 46 - 46
  • [3] Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer.
    Heilmann, V
    Eggemann, H
    Sommer, H
    Heinrich, G
    Blohmer, JU
    Mallmann, PK
    Krabisch, P
    Klare, P
    Schilling, J
    Kittel, K
    Elling, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
  • [4] A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
    Venturini, M.
    Bighin, C.
    Puglisi, F.
    Olmeo, N.
    Aitini, E.
    Colucci, G.
    Garrone, O.
    Paccagnella, A.
    Marini, G.
    Crino, L.
    Mansutti, M.
    Baconnet, B.
    Barbato, A.
    Del Mastro, L.
    BREAST, 2010, 19 (05): : 333 - 338
  • [5] Phase II study of weekly pegylated liposomal doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
    Holmes, F
    Blum, JL
    Kruger, S
    Ratnam, S
    Liu, L
    Boehm, KA
    Asmar, L
    O'Shaughnessy, JA
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S130 - S130
  • [6] Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
    Schmid, Peter
    Krocker, J.
    Kreienberg, R.
    Klare, P.
    Kittel, K.
    Sommer, H.
    Heinrich, G.
    Steck, T.
    Lichtenegger, W.
    Elling, D.
    Kuemmel, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 401 - 406
  • [7] Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
    Peter Schmid
    J. Krocker
    R. Kreienberg
    P. Klare
    K. Kittel
    H. Sommer
    G. Heinrich
    T. Steck
    W. Lichtenegger
    D. Elling
    S. Kümmel
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 401 - 406
  • [8] Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
    Curtit, E.
    Nouyrigat, P.
    Dohollou, N.
    Levy, E.
    Lortholary, A.
    Gligorov, J.
    Facchini, T.
    Jaubert, D.
    Maille, N.
    Pivot, X.
    Grange, V.
    Cals, L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (16) : 2396 - 2402
  • [9] Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer
    Alexopoulos, A
    Karamouzis, MV
    Stavrinides, H
    Ardavanis, A
    Kandilis, K
    Stavrakakis, J
    Georganta, C
    Rigatos, G
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 891 - 895
  • [10] Non Pegylated Liposomal Doxorubicin (Myocet) Plus Vinorelbine Versus Myocet Plus Cyclophosphamide as First Line in Locally Advanced (Labc) or Metastatic Breast Cancer (Mbc): A Randomized Multicenter Phase II Trial
    Lorusso, V.
    Leo, S.
    Forcignano, R.
    Giotta, F.
    Bordonaro, R.
    Filippelli, G.
    Del Prete, S.
    Maiello, E.
    Gebbia, V.
    Pisconti, S.
    Colucci, G.
    ONCOLOGY, 2009, 77 : 151 - 151
12345